 | |
| Clinical data | |
|---|---|
| Other names | 6-(2-(Methylamino)propyl)-2,3-dihydrobenzofuran; 1-(2,3-Dihydrobenzofuran-6-yl)-N-methylpropan-2-amine |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C12H17NO |
| Molar mass | 191.274 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
6-MAPDB, also known as6-(2-(methylamino)propyl)-2,3-dihydrobenzofuran, is achemical compound which may be anentactogen of thedihydrobenzofuran family. It is structurally related to drugs like6-APDB and6-MAPB, which have similar effects to MDMA and have been used as recreational drugs. 6-MAPDB has never been studied to determine itspharmacological activity, though it is theN-methyl derivative of 6-APDB which is known to be aselective serotonin releaser.[1]
6-MAPDB was banned in the UK in June 2013 as atemporary class drug along with 9 other related compounds, despite having never been sold as a street drug itself. This was due to concerns that it would have similar effects to drugs such as6-APB that had been widely sold already, and 6-MAPDB might therefore be likely to become used recreationally also, if it were not banned preemptively.[2]
